Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Use of a pMDI with a holding chamber is noninferior to nebulization for delivering salbutamol in children with asthma exacerbations.

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The FDA has removed the REMS program requirements for embryofetal toxicity risk from all endothelin receptor antagonist medications.

The FDA published over 200 response letters sent as replies to drug and biological product applications in order to increase transparency.

Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

PRISm may be a precursor to COPD regardless of an individual’s smoking status, although smokers have faster lung function decline.

Increased risk for all-cause and CVD mortality in OSA may be linked to a severe phenotype marked by objective excessive daytime sleepiness.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

The likelihood of antiviral prescribing and dispensing among patients with influenza varied by care setting, patient age, and underlying medical conditions.